Objective: The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)b/d and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. Methods: Studies were conducted in wild-type and Pparb/d-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. Results: Increased VLDLR levels were observed in liver of Pparb/d-null mice and in Pparb/d-knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2a (eIF2a) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARb/d mRNA abundance and DNA-binding activity compared with control subjects. Conclusions: Overall, these findings provide new mechanisms by which PPARb/d and FGF21 regulate VLDLR levels and influence hepatic steatosis development.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disorder, and its growing prevalence has increased to reach worldwide epidemic proportions [1] . NAFLD encompasses a spectrum of liver injuries ranging from hepatic steatosis, defined by the excessive accumulation of triglycerides in the liver, to the most severe condition of non-alcoholic steatohepatitis (NASH). In addition, NAFLD is an important risk factor for the development of obesity-related pathologies including insulin resistance, type 2 diabetes mellitus (T2DM), and cardiovascular diseases [2] . Hepatic triglyceride levels are regulated by multiple mechanisms such as de novo synthesis, fatty acid oxidation, lipolysis, dietary fat consumption, and the secretion and hepatic delivery of lipoprotein particles [3e5] . Recently, it has been reported that very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis [6] . VLDLR belongs to the low-density lipoprotein (LDL) receptor family and is widely expressed in the brain, heart, skeletal muscle, and adipose tissue, whereas its expression is very low in the liver under normal conditions [7, 8] . This receptor binds apolipoprotein E (apoE) triglyceride-rich lipoproteins such as chylomicrons, VLDL, and intermediate density lipoproteins, leading to lipid entry into the cell through lipoprotein lipase (LPL)-dependent lipolysis or receptor-mediated endocytosis [9e12] . As a result, a link has been established between VLDLR levels and plasma triglyceride levels [13] . VLDLR-null mice are leaner, display normal blood lipids [14] and are protected from obesity induced by HFD feeding or leptin deficiency [15] . However, following fasting or exposure to a HFD, these animals show increased plasma triglyceride levels [15, 16] . In recent years, it has been reported that VLDLR is regulated by several transcription factors, including Peroxisome Proliferator-Activated Receptor (PPAR) g in adipose tissue [12] and hypoxia-inducible factor 1a (HIF-1a) in the heart [17] , contributing to lipid deposition in both tissues. In liver, the upregulation of VLDLR levels has been reported to be dependent on the activation of oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in alcoholic liver disease [18] , whereas stimulation of activating transcription factor 4 (ATF4) signaling during endoplasmic reticulum (ER) stress induces hepatic steatosis via increase VLDLR by enhancing lipoprotein delivery to the liver [6] . In addition, hepatic VLDLR upregulation plays an essential role in the triglyceride-lowering effect of fenofibrate through PPARa activation [19] . However, little is known about the effects of PPARb/d on VLDLR regulation in the liver. PPARb/d is a ligand-activated transcription factor involved in the regulation of glucose and lipid homeostasis [20] , and it has been proposed as a therapeutic target for the treatment of metabolic syndrome [21] . Thus, genetic manipulation of PPARb/d as well as its activation by agonists attenuate dyslipidemia and hyperglycemia, improve whole-body insulin sensitivity, and prevent diet-induced obesity [22] . In this study, we show that Pparb/d deficiency regulates VLDLR levels through Nrf2 and ATF4-dependent mechanisms, whereas fibroblast growth factor 21 (FGF21) deficiency exacerbates ER stress-induced VLDLR levels, contributing to the progression of hepatic steatosis. Finally, our findings show that in humans with severe hepatic steatosis, increased levels of VLDLR accompany a reduction in PPARb/d activity.
RESEARCH DESIGN AND METHODS

Reagents
Control, VLDLR, HRI, ATF4, and Nrf2 siRNA were purchased from Santa Cruz (Dallas, TX) and PPARb/d siRNA from GE Dharmacon (Lafayette, CO). Mouse FGF21 neutralizing antibody was purchased from Antibody and Immunoassays Services (Hong Kong, China) and human recombinant FGF21 from R&D Systems (Minneapolis, MN). Triglyceride levels were measured using a commercial kit (Sigma, St. Louis, MO). were cultured in DMEM supplemented with 10% serum, at 37 C/5% CO 2 . Primary mouse hepatocytes were isolated from non-fasting male C57BL/6 mice (10e12 weeks old) by perfusion with collagenase as described elsewhere [26] . siRNA transfections were performed with Lipofectamine 2000 (Life Technologies).
Human samples
Subjects were recruited by the Gastroenterology Department at the Shahid Beheshti University of Medical Sciences (Tehran, Iran) with the approval of the Ethical Committee of the University Review Board of the participating Taleghani Hospital. NAFLD subjects (Table S1) were diagnosed according to WHO criteria. Patients were considered as having potential liver steatosis if they had abnormal liver blood tests. Alcohol consumption had to be less than 20 g/day for the past 5 years, as assessed using a standard questionnaire. In addition, liver specimen had to be compatible with NAFLD [27] , without any pattern suggestive of other cause. Patients were not included if they had another cause of chronic liver disease, complicated cirrhosis, or received putative antifibrotic treatment in the past 6 months. Liver biopsies were performed at Taleghani Hospital in 2012e2013 using a Meghini 16 swg (1.6 mm) Â 70 mm syringe. The material consisted of 15 needle biopsies from adult patients. Specimens were immediately sent for pathology assessment by routine procedures; two biopsies were required to obtain an acceptable specimen. All the biopsies were reviewed by the pathologist and the presence of steatosis was graded in grade 0 with <5% of hepatocytes presenting steatosis (control group) (n ¼ 5), grade 2 with 33e66% of hepatocytes presenting steatosis (n ¼ 4), and grade 3 with more than 66% steatotic hepatocytes (n ¼ 6). Written informed consent was obtained from each patient included in the study and the study protocol conformed to the ethical guidelines of the 2013 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
RNA preparation and quantitative RT-PCR
The relative levels of specific mRNAs were assessed by Real-Time RT-PCR, as previously described [28] . Primer sequences used for Real-Time RT-PCR are displayed in Table S2 .
Immunoblotting
Isolation of total and nuclear extracts was performed as described elsewhere [28] . 
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was performed using double-stranded oligonucleotide for the consensus binding site of PPRE (Santa Cruz Biotechnology). Nuclear extracts (NE) were isolated as previously reported [28] . Oligonucleotides were labeled by incubating the following reaction at 37 C for 2 h: 2 mL oligonucleotide (1.75 pmol/mL), 2 mL of 5X kinase buffer, 1 mL of T4 polynucleotide kinase (10 U/mL), and 2.5 mL [g- antibody for supershift assays were added and incubated for 15 min on ice. Subsequently, the labeled probe (100,000 cpm) was added and the reaction was incubated for an additional 15 min on ice. Finally, protein-DNA complexes were resolved by electrophoresis at 4 C on 5% (w:v) polyacrylamide gels in 0.5X Tris-borate-EDTA buffer and subjected to autoradiography.
Hematoxylin-eosin and Oil Red and staining
We performed hematoxylin-eosin and Oil Red O staining as previously reported [28] . ORO staining was quantified using Image J software.
Statistical analyses
Results are expressed as means AE S.D. Significant differences were established by two-way ANOVA using the GraphPad Instat program (GraphPad Software V5.01) (GraphPad Software Inc., San Diego, CA). When significant variations were found by two-way ANOVA, the TukeyeKramer multiple comparison post-test was performed. Differences were considered significant at p < 0.05.
RESULTS
Pparb/d
À/e mice show increased hepatic VLDLR levels First, we examined whether Pparb/d-deficiency affected VLDLR levels. VLDLR mRNA and protein levels were increased in the livers of Pparb/ d À/À mice compared with wild-type littermates ( Figure 1A and B). This increase in VLDLR was accompanied by the presence of hepatic steatosis in Pparb/d À/À mice compared to wild-type littermates, as demonstrated by ORO and hematoxylin-eosin staining and hepatic triglyceride quantification ( Figure 1C and D), whereas differences in plasma triglyceride levels did not reach statistical significance (data not shown). In accordance with the observations in the liver of Pparb/ddeficient mice, siRNA knockdown of Pparb/d in primary hepatocytes ( Figure S1B ) led to enhanced Vldlr mRNA and protein levels ( Figure 1E and F). Similarly, transfection of human Huh-7 hepatocytes with siRNA against PPARb/d caused a significant increase in VLDLR mRNA levels ( Figure 1G ) and in cellular lipid accumulation ( Figure 1H ). Next, we focused on ATF4 as the potential transcription factor responsible for the increase in VLDLR in Pparb/d-deficient cells. Although ATF4 is activated by ER stress through eukaryotic translation initiation factor 2a (eIF2a), the increase in phosphorylated eIF2a and activation of its downstream ATF4 signaling pathway can occur independently of ER stress, since eIF2a can also be phosphorylated by other kinases, including the heme-regulated eIF2a kinase (HRI) [29] . Interestingly, Pparb/d À/À mice showed increased levels of HRI, which in turn activates the eIF2a-ATF4 pathway [28] , suggesting that HRI might also regulate VLDLR levels. In agreement with this, siRNA knockdown of Hri ( Figure S1A ) in primary hepatocytes caused a reduction in VLDLR mRNA and protein levels ( Figure 2A ). Moreover, two well-known HRI activators [30] , BTCtFPU and BTdCPU, upregulated VLDLR mRNA and protein levels in human Huh-7 hepatocytes ( Figure 2B ), and BTdCPU also upregulated VLDLR levels in the liver of mice treated with this compound ( Figure 2C ). Next, we checked whether other transcription factors such as Nrf2, known to be involved in the upregulation of hepatic VLDLR [18] , might be responsible for the increase in the expression of this gene in the livers of Pparb/d-null mice. Interestingly, livers of Pparb/d À/À mice showed increased levels of phosphorylated Nrf2, an indicator of the activity of this transcription factor [31] , compared with wild-type littermates ( Figure 2D ). In agreement with this, the mRNA and protein levels of the Nrf2-target gene NAD(P)H quinone dehydrogenase 1 (Nqo1) were also upregulated ( Figure 2D and E).
To confirm the involvement of HRI, ATF4, and Nrf2 in the upregulation of Vldlr in the context of Pparb/d deficiency, we performed siRNA studies in primary hepatocytes. Knockdown of Pparb/d increased the expression of Vldlr, but this increase was prevented by siRNA transfection against Atf4, Nrf2, or Hri ( Figure 2F ). Two ATF4-target genes, Trb3 [28] and Fgf21 [32] , were upregulated by Pparb/d knockdown, but this was prevented by transfecting siRNA against either Atf4 or Hri ( Figure S1C and D) . Similarly, expression of Nrf2 and two of its target genes, Nqo1 and Ho-1, increased following Pparb/d knockdown and this was prevented by siRNA transfection against Nrf2 ( Figure S1EeG ). These findings indicate that Pparb/d deficiency increases Vldlr expression through the HRI-eIF2a-ATF4 and Nrf2 pathways. Figure 3H ). Overall, these findings suggest that ATF4 and Nrf2 activation by tunicamycin in the presence of Pparb/d deficiency intensifies the increase in hepatic VLDLR.
3.3. FGF21 protects against hepatic steatosis and the upregulation of VLDLR levels caused by ER stress Since FGF21 suppresses the eIF2a-ATF4 pathway through a negative feedback [34] , we hypothesized that the reported increase in FGF21 observed in Pparb/d-deficient mice [28] Figure 4C ). No changes in these parameters were observed in wild-type mice injected with the neutralizing antibody ( Figure S2A and B). VLDLR regulation by FGF21 was confirmed in the livers of Fgf21-deficient mice. These mice showed increased hepatic triglyceride accumulation ( Figure 4D ), a process which has been reported to be age-dependent [35] , and Vldlr mRNA ( Figure 4E ) and protein abundance accompanied by enhanced eIF2a phosphorylation and ATF4 protein levels ( Figure 4F) . Similarly, the expression levels of two Atf4-target genes, Trb3 and Chop, were also increased in the livers of Fgf21 À/À mice compared with wild-type mice ( Figure S2C and D) , although Chop did not reach statistical significance. In contrast, phosphorylated levels of Nrf2 were reduced in Fgf21 À/À mice ( Figure 4G ), rendering its involvement in VLDLR upregulation unlikely. Finally, we examined the effects of recombinant FGF21 treatment on ER-stress-induced VLDLR levels. In Huh-7 hepatocytes FGF21 significantly reduced the increase in VLDLR and CHOP expression ( Figure 5A and B) and in VLDLR protein levels caused by tunicamycin, and these reductions were accompanied by a decrease in the levels of phospho-eIF2a ( Figure 5C ). Similarly, administration of FGF21 reduced the increase in both the expression and the protein levels of VLDR caused by tunicamycin in liver ( Figure 5D and E). These findings suggest that FGF21 may protect against hepatic steatosis by limiting the increase in VLDLR levels via attenuation of the eIF2a-ATF4 pathway.
3.4. VLDLR upregulation is intensified by fructose feeding in the liver of Pparb/d-null mice Fructose feeding leads to hepatic steatosis [36] . Consequently, we explored whether VLDLR was involved in the effects of fructose on liver in the context of Pparb/d deficiency. As previously shown [25] , feeding wild-type mice (C57BL/6X129/SV genetic background) with fructose did not result in hepatic steatosis ( Figure 6A and B). However, Pparb/ d À/À mice exposed to fructose exhibited a clear and intense steatosis.
When hepatic VLDLR mRNA and protein levels were assessed, waterfed Pparb/d À/À mice showed a significant increase that was intensified by fructose feeding ( Figure 6C and D). As previously reported [37] , fructose feeding increased Fgf21 expression in liver of wild-type mice ( Figure S3A ), indicating that despite the lack of induction of triglyceride accumulation in the liver of wild-type mice, fructose feeding was efficacious. This increase was exacerbated in Pparb/d-deficient mice. In contrast, expression of the ATF4-target gene Chop was unaffected in fructose-fed Pparb/d À/À mice ( Figure S3B ), rendering it unlikely that this pathway was involved in the VLDLR upregulation observed in the liver of these mice. Consistent with the trend observed in VLDLR, phospho-Nrf2 levels and the expression of its target gene Nqo1 were elevated in livers of fructose-fed Pparb/d À/À mice ( Figure 6E and F). The oxidative stress status measured by the lipid peroxidized product MDA and H 2 O 2 was significantly increased only in fructose-fed Pparb/d À/À mice ( Figure 6G and H), suggesting that enhanced ROS levels was the stimulus responsible for the increase in the activity of this redox transcription factor. To clearly demonstrate the involvement of Nrf2, the expression of this gene and that of Pparb/ d was knocked down by siRNA transfection in mouse primary hepatocytes. As previously shown, Pparb/d knockdown increased the expression of Vldlr and this increase was intensified by incubation with fructose ( Figure 6I ). However, Nrf2 knockdown abrogated the increase caused by the reduction in Pparb/d expression and incubation with fructose ( Figure 6I ). The increase in VLDLR expression was also observed in human hepatocytes transfected with siRNA against PPARb/d and this effect was specific for fructose, since it was not observed in hepatocytes exposed to a related carbohydrate such as mannitol ( Figure S3C ). Overall, these data suggest that in the context of Pparb/d deficiency, fructose induces ROS production, a well-known activator of Nrf2, which in turn increases VLDLR levels and ultimately produces hepatic steatosis by increasing lipoprotein delivery to the liver.
3.5. VLDLR content is increased in the liver of patients with steatosis Our findings in in vitro and animal models suggest a new potential pathway that might contribute to NAFLD. In this pathway, a reduction in PPARb/d levels might result in activation of both ATF4 and Nrf2, which in turn would enhance VLDLR levels, leading to increased VLDL (triglyceride) delivery to the liver. The contribution of this potential pathway was explored in liver biopsies of patients classified into three grades based on the percentage of hepatocytes presenting steatosis: grade 0 (<5%), grade 2 or moderate steatosis (33e66%) and grade 3 or severe steatosis (>66%) ( Figure 7A ). VLDLR mRNA expression ( Figure 7B ) and protein levels ( Figure 7C ) were increased in patients suffering hepatic steatosis. The increase in VLDLR levels was accompanied by a reduction in PPARb/d mRNA abundance that only reached statistical significance in livers of patients with severe hepatic steatosis ( Figure 7D ). The expression of the PPARb/d-target genes involved in fatty acid oxidation, PDK4 and CPT-1a, was reduced in the livers of patients with steatosis ( Figure 7D ). Consistent with the reduced levels of PPARb/d, the DNA-binding activity of this transcription factor assessed by EMSA showed a reduction in patients with hepatic steatosis, especially in those with severe hepatic steatosis ( Figure 7E ). The reduction in PPARb/d expression and activity in patients with severe hepatic steatosis was accompanied by an increase in HRI, TRB3, and NQO1 expression ( Figure 7F ), suggesting that the increase in VLDLR levels in humans with severe hepatic steatosis in the context of reduced PPARb/d levels might be the result of activation of the HRI-eIF2a-ATF4 and Nrf2 pathways. Expression of ATF4-target gene FGF21 was significantly increased only in the patients with severe steatosis ( Figure 7G ), whereas expression of its receptors, b-klotho and FGFR1c, was reduced, although the reduction of the receptor did not reach significance, suggesting that the effect of this hormone might be attenuated ( Figure 7G ).
DISCUSSION
Here we present evidence that VLDLR is regulated by PPARb/d and FGF21. The reported increase in VLDLR in Pparb/d null macrophages Original Article [38] , prompted us to examine whether Pparb/d-null mice showed increased VLDLR levels and determine its contribution to NAFLD and the mechanisms involved. Our findings indicate that in Pparb/d-null mice, HRI activation in liver increases VLDLR levels through the eIF2a-ATF4 pathway (Figure 8 ). Despite this, HRI activators do not increase hepatic steatosis; on the contrary, these compounds also increased FGF21 levels and this hormonal factor improved glucose intolerance and hepatic triglyceride accumulation induced by feeding a HFD [28] . In addition, Pparb/d-deficiency also results in the activation of Nrf2, another transcription factor that contributes to increase VLDLR levels [18] . Under conditions of Pparb/d-deficiency, the increase in VLDLR levels would contribute to hepatic steatosis. In addition, stimulation of ER stress induces hepatic steatosis through VLDLR [6] , and this process might be exacerbated in Pparb/d-null mice through a higher activation of both ATF4 and Nrf2, suggesting that the absence of PPARb/d contributes to intensify ER stress-induced fatty liver. It has previously been reported that the PPARb/d agonist GW501516 promotes glucose flux to the pentose phosphate pathway and fatty acid synthesis in liver [39] , establishing a discrepancy with the findings of this manuscript. However, a time-course study demonstrated that GW501516 induces accumulation of liver lipids following 4 wk of treatment, but this turned into a reduction in the content of hepatic lipids after 8 wk. of GW501516 treatment [40] , probably as the result of an increase in fatty acid oxidation. Therefore, long treatments with GW501516 reduce hepatic lipids, which is consistent with the increase in liver lipids observed in Pparb/d-null mice. FGF21 has emerged as an important regulator of glucose and lipid metabolism and hence is a promising agent for the treatment of obesity, NAFLD, insulin resistance, and type 2 diabetes mellitus [41] . This study also suggests that the reported enhanced FGF21 levels in Pparb/d-deficient mice [28] prevent a higher increase in VLDLR levels and hepatic triglyceride accumulation. This effect of FGF21 is the result of a negative feedback loop by which this hormone suppresses the eIF2a-ATF4 pathway [28, 34] . In fact, we show here that blocking FGF21 increases VLDLR levels and hepatic steatosis. In agreement with this, Fgf21 À/À mice showed increased hepatic activation of the eIF2a-ATF4 pathway and VLDLR levels, suggesting that this receptor may account for part of the hepatic steatosis observed in these mice. Thus, FGF21 can prevent NAFLD by increasing hepatic fatty acid oxidation and reducing lipid synthesis [41] , and our findings indicate that this hormone may also prevent NAFLD by downregulating VLDLR levels.
Fructose feeding increases hepatic steatosis, but this process is influenced by the genetic background of the mice. In our study, feeding wild-type mice (C57BL/6X129/SV genetic background) with fructose did not result in hepatic steatosis, although fructose feeding was successful, as demonstrated by the increase in Fgf21 expression, probably through carbohydrate response element binding protein (ChREBP)-mediated mechanisms, as previously reported [37] . However, Pparb/d-null mice of the same genetic background fed with fructose showed hepatic steatosis, and this was accompanied by higher hepatic VLDLR levels. Our findings demonstrate that in the context of Pparb/d deficiency, fructose induces ROS production, leading to an increase in phospho-Nrf2 levels and therefore in its activity. A step further, our siRNA studies demonstrated that this transcription factor was responsible for fructose-induced Vldlr expression in primary hepatocytes. An analysis of human samples from patients with hepatic steatosis showed an increase in the liver protein content of VLDLR compared with control subjects. Interestingly, a reduction in PPARb/d levels and/ or activity, as demonstrated by EMSA and the expression of its target genes, was also observed in the liver of these patients, suggesting that [28] ) and by activators of this kinase (BTdCPU) may increase the levels of VLDLR through the eIF2a-ATF4 pathway. ER stress can also activate the eIF2a-ATF4 pathway leading to an increase in the expression of VLDLR and FGF21. This hormone suppresses the eIF2a-ATF4 pathway through a negative feedback mechanism and thereby it also regulates the levels of VLDLR. ER stress also enhances the activity of Nrf2, a transcription factor reported to upregulate the expression of Fgf21 (reference [19] ). Fructose feeding increases the levels of ROS and the activity of Nrf2 providing a mechanism for the increase of the levels of VLDLR. All these mechanisms may result in an increase in the levels of VLDLR causing hepatic steatosis. TG: triglyceride.
the relationship between PPARb/d and VLDLR observed in mice might also operate in humans with hepatic steatosis. Targeting PPAR isotypes for the treatment of fatty liver disease has been extensively studied, mainly in the case of PPARa [42, 43] . However, although the beneficial effect of activating PPARa for NAFLD has been proven in several mouse models [42, 43] , fibrates, which are PPARa agonists, do not correct NAFLD in humans [44] . In contrast, long-term activation of PPARb/d can improve hepatic steatosis by activating fatty acid oxidation in different mouse models [45, 46] , whereas clinical studies have also demonstrated a reduction of hepatic fat content in humans upon treatment with PPARb/d agonists [47, 48] . Our findings show that in patients with hepatic steatosis the reduction in PPARb/d activity is accompanied by an increase in VLDLR levels. It remains to be studied whether in the clinical setting PPARb/d agonists improve hepatic steatosis by regulating VLDLR abundance. Moreover, since we have reported that PPARb/d activation in mice increases PPARa expression and activity and enhances the hepatic levels of the endogenous PPARa ligand 16:0/18:1-phosphatidylcholine [49] , we cannot discard that the reduction of PPARb/d activity may also affect the activity of PPARa. Consistent with this, drugs combining PPARa and PPARb/d isotype agonism are a promising treatment for NAFLD. In fact, the dual PPARa/b(d) agonist elafibranor (GFT505) shows antisteaotic effects in rodent models [50] , and, in abdominally obese subjects, it improves hepatic and peripheral insulin sensitivity and probably NAFLD, although liver fat content was not measured [51] .
On the other hand, the increase in hepatic FGF21 expression in patients suffering hepatic steatosis is in agreement with previous studies [52] , and it has been considered to be the result of a resistance to this hormone [53] , implying that the lack of FGF21 activity may also contribute to increase VLDLR levels in hepatic steatosis. It is important to point out that the low number of patients analyzed is a limitation of this part of the study and precludes that VLDLR plays a role in NAFLD although it might correlate with liver fat accumulation.
CONCLUSIONS
The findings of this study suggest that Pparb/d-deficiency results in an increase in VLDLR levels, whereas FGF21 prevents the increase in hepatic VLDLR levels. In patients with hepatic steatosis, a reduction in the levels and/or activity of PPARb/d was accompanied by an increase in VLDLR abundance, suggesting that this crosstalk might be involved in fatty liver development. Overall, these data suggest that modulation of PPARb/d and/or FGF21 activity might be a key therapeutic target for the treatment of hepatic steatosis by regulating VLDLR abundance.
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